Monoclonal antibodies that suppress B cell growth and/or differentiation
AssigneeOchsner Clinic Foundation
InventorsYong Sung Chol, Li Li
Life of this patent
Estimating the term…
Abstract
The present invention provides monoclonal antibodies which interfere with the interactions between FDCs and B cells, thereby suppressing the proliferation and/or differentiation of B cells in lymphoid follicles. The monoclonal antibodies of the present invention are useful for treating follicular lymphomas, multiple myeloma as well as autoimmune diseases.
Claims26
Monoclonal antibody 8D6 (ATCC#).
Monoclonal antibody 4G10 (ATCC#).
A functional derivative of mAb 8D6 (ATCC#), wherein said functional derivative suppresses B cell growth or differentiation.
The functional derivative of mAb 8D6 (ATCC#), wherein said functional derivative is selected from Fab, Fab′, F(ab′)2, a single chain antibody, or a chimeric antibody.
A functional derivative of mAb 4G10 (ATCC#), wherein said functional derivative suppresses B cell growth or differentiation.
The functional derivative of mAb 4G10 (ATCC#), wherein said functional derivative is selected from Fab, Fab′, F(ab′)2, a single chain antibody, or a chimeric antibody.
A pharmaceutical composition comprising mAb 8D6 and a pharmaceutically-acceptable carrier.
A pharmaceutical composition comprising a functional derivative of mAb 8D6 (ATCC#) and a pharmaceutically-acceptable carrier, wherein said functional derivative suppresses B cell growth or differentiation.
A pharmaceutical composition comprising mAb 4G10 (ATCC#). and a pharmaceutically-acceptable carrier.
A pharmaceutical composition comprising a functional derivative of mAb 4G10 (ATCC#) and a pharmaceutically-acceptable carrier, wherein said functional derivative suppresses B cell growth or differentiation.
A pharmaceutical composition comprising (1) a pharmaceutically-acceptable carrier, (2) mAb 8D6 (ATCC#) or a functional derivative of mAb 8D6, and (3) mAb 4G10 or a functional derivative of mAb 4G10.
A method of treating a subject suffering a pathological condition characterized by abnormal growth or differentiation of B cells, comprising administering to said subject a therapeutically effective amount of mAb 8D6 or a functional derivative thereof.
A method of treating a subject suffering a pathological condition characterized by abnormal growth or differentiation of B cells, comprising administering to said subject a therapeutically effective amount of mAb 4G10 or a functional derivative thereof.
A method of treating a subject suffering a pathological condition characterized by abnormal growth or differentiation of B cells, comprising administering to said subject a therapeutically effective amount of (1) mAb 4G10 or a functional derivative thereof, and (2) mAb 8D6 or a functional derivative thereof.
A hybridoma cell line, having the ATCC deposit number ______.
A hybridoma cell line, having the ATCC deposit number ______.
Dependencies are inferred from the claim text.